DNA Repair Capacity and Clinicopathological Characteristics in Puerto Rican Hispanic/Latino Patients with Metastatic Castration-Resistant Prostate Cancer DOI Open Access
Jaime Matta, Carmen Ortíz, Jarline Encarnación-Medina

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(2), P. 279 - 279

Published: Jan. 16, 2025

Background: Prostate cancer (PCa) accounts for 22% of the new cases diagnosed in Hispanic/Latino (H/L) men US. PCa has highest incidence (38.3%) and mortality (16.4%) among all types Puerto Rico. We previously showed that patients (n = 41) have a significant reduction 59% their levels DNA repair capacity (DRC) when compared to controls 14). This study aimed evaluate DRC through nucleotide excision (NER) pathway first time 16 Rican H/L with metastatic castration-resistant (mCRPCa) while establishing comparisons indolent aggressive disease. Methods: Blood samples clinicopathological data from 71) 25) were evaluated. stratified into mCRPCa 16), 31), 24). NER measured lymphocytes CometChip assay. The stratification by Gleason score (GS) was GS6 7), GS7 23), GS ≥ 8 20), 16). Results: Significant statistical differences found comparing values any other four patient groups. had lowest mean level groups studied. 6.65%, controls, this represented statistically 62% (p < 0.0001). Further analysis performed contributions age, anthropometric measurements, prostate-specific antigen (PSA) DRC. Kaplan–Meier curves revealed survival probability decreased approximately 50% 30 months. pilot uses blood-based phenotypic assay present report at global patients. Conclusions: evaluated mCRPCa. between three months, only 20% cohort alive 50 confirming lethality population. represents using

Language: Английский

DNA Repair Capacity and Clinicopathological Characteristics in Puerto Rican Hispanic/Latino Patients with Metastatic Castration-Resistant Prostate Cancer DOI Open Access
Jaime Matta, Carmen Ortíz, Jarline Encarnación-Medina

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(2), P. 279 - 279

Published: Jan. 16, 2025

Background: Prostate cancer (PCa) accounts for 22% of the new cases diagnosed in Hispanic/Latino (H/L) men US. PCa has highest incidence (38.3%) and mortality (16.4%) among all types Puerto Rico. We previously showed that patients (n = 41) have a significant reduction 59% their levels DNA repair capacity (DRC) when compared to controls 14). This study aimed evaluate DRC through nucleotide excision (NER) pathway first time 16 Rican H/L with metastatic castration-resistant (mCRPCa) while establishing comparisons indolent aggressive disease. Methods: Blood samples clinicopathological data from 71) 25) were evaluated. stratified into mCRPCa 16), 31), 24). NER measured lymphocytes CometChip assay. The stratification by Gleason score (GS) was GS6 7), GS7 23), GS ≥ 8 20), 16). Results: Significant statistical differences found comparing values any other four patient groups. had lowest mean level groups studied. 6.65%, controls, this represented statistically 62% (p < 0.0001). Further analysis performed contributions age, anthropometric measurements, prostate-specific antigen (PSA) DRC. Kaplan–Meier curves revealed survival probability decreased approximately 50% 30 months. pilot uses blood-based phenotypic assay present report at global patients. Conclusions: evaluated mCRPCa. between three months, only 20% cohort alive 50 confirming lethality population. represents using

Language: Английский

Citations

0